The COVID-19 Inactivated Vaccine segmentation by application distinguishes three primary demand drivers that collectively shape market volume. National Immunization Programs represent the largest share, accounting for roughly 55 % of total sales, as governments procure bulk doses for mass rollout to adult and senior populations. This segment drives economies of scale, influencing pricing structures and supply-chain logistics. The Travel & Occupational category, contributing about 25 % of the market, targets individuals requiring prophylaxis for international movement or high‑risk occupational exposure, such as airline crews and frontline healthcare workers; procurement is typically episodic and price‑sensitive, prompting manufacturers to offer flexible packaging. Finally, Clinical Trials and investigational use comprise the remaining 20 %, where doses are allocated to research institutions and biotech firms for comparative efficacy studies, safety monitoring, and next‑generation formulation testing. Each application tier imposes distinct regulatory, distribution, and revenue dynamics, together defining the overall market size and growth trajectory.